Space Stock Face-Off: Is Rocket Lab or AST SpaceMobile Worth Your Money Right Now?

Rocket Lab reported Q1 revenue of $200.3 million, up 63.5% year over year, and beat on sales, earnings, and guidance, while narrowing its per-share loss to $0.07 from $0.12 a year ago. AST SpaceMobile missed on all three key metrics, posting a $0.66 per-share loss versus a $0.21 expected loss, revenue of $14.7 million versus $37.5 million expected, and full-year revenue guidance of about $175 million below consensus. The article favors Rocket Lab as having the clearer path to profitability, but says both stocks remain expensive and unappealing near term.

Analysis

The market is treating “space” as one thematic basket, but the underlying businesses are diverging sharply. RKLB is moving toward an industrial services compounder: each acquisition broadens its addressable wallet share and reduces dependence on the lumpy launch cycle, which should make revenue more resilient and multiple supportable even before GAAP profitability. ASTS, by contrast, is still in the capital-formation phase; the key issue is not just execution risk, but whether the funding curve outruns the network buildout before the market’s patience resets.

Second-order, the winner here is likely the supply chain around orbital hardware rather than the headline equities. If Rocket Lab keeps scaling vertically, it can pull forward demand for precision components, software, and acquisition targets in small-cap aerospace, while ASTS’s path implies persistent need for launch capacity, satellite manufacturing, and ground network vendors — but with financing risk that can force harsher terms if milestones slip. The balance-sheet asymmetry matters: ASTS can absorb one or two misses, but repeated delays could quickly convert a growth story into a dilution story.

The consensus may be underestimating how much the SpaceX IPO changes the tape. A public SpaceX would likely compress the valuation premium across the entire category, which means near-term beats may not protect multiple contraction if investors gain a cleaner way to express the sector beta. That makes RKLB the better relative long only if you believe it can decouple into a diversified aerospace platform; ASTS is more vulnerable because its value is further out on the curve and more sensitive to any shift in discount rate or risk appetite.

Catalyst timing differs materially: RKLB can re-rate over the next 1-2 quarters if margin expansion continues and Neutron milestones stay on track, while ASTS has a binary 1-3 month window around launch cadence and satellite deployment. If ASTS misses another deployment target, the market will likely reprice it not as a network-in-build but as a financing overhang. For both names, sentiment is currently doing part of the valuation work — which cuts both ways.

Key Decisions for Investors

• Long RKLB / short ASTS as a relative-value pair for the next 3-6 months: RKLB has better execution visibility and lower dilution risk; ASTS has higher upside but materially worse downside if launch cadence slips.
• For aggressive accounts, sell ASTS call spreads or buy put spreads into any strength over the next 30-60 days, targeting a reversion trade if the market starts discounting satellite-delivery slippage or future equity raises.
• Avoid initiating fresh long ASTS positions before the next launch window; wait for actual in-orbit success and a clearer beta-service date, because the stock is still in a milestone-asymmetry regime where one miss can overwhelm multiple future beats.
• Add RKLB on pullbacks only if the market ignores the vertical-integration story after the next earnings print; the cleaner setup is a medium-term long with a 6-12 month horizon, but size it with the expectation that a SpaceX IPO could cap the multiple.
• If you want category exposure without single-name execution risk, prefer a basket approach and keep net exposure light until the SpaceX IPO resets relative valuations across the space complex.